2024-04-25T10:29:44-05:00 2023-06-30 Maginnis Knechtel & McIntyre LLP 300 W Colorado Blvd Pasadena CA 91105 990 2022-07-01 952916590 DOHENY EYE INSTITUTE % STEVE MACGREGOR DOHE 3233427100 150 ORANGE GROVE AVE PASADENA CA 91103 MARISSA GOLDBERG CEO 3233427100 2024-04-18 true MARISSA GOLDBERG 999009999 true X Linda E G Ballesteros P00366852 6264493466 2024-04-18 2 2022 2023-04-26 12:10:37Z X MARISSA GOLDBERG 150 ORANGE GROVE AVE PASADENA CA 91103 60396461 false X WWW.DOHENY.ORG X 1947 CA TO FURTHER THE CONSERVATION, IMPROVEMENT AND RESTORATION OF HUMAN EYESIGHT. 14 13 147 25 33375 32375 3578935 5232088 5183210 5447881 57175716 14317448 163092 493759 66100953 25491176 0 0 0 0 13369356 14774256 0 0 625541 6508402 7842762 19877758 22617018 46223195 2874158 229360664 227631156 4674006 4896913 224686658 222734243 X TO FURTHER THE CONSERVATION, IMPROVEMENT AND RESTORATION OF HUMAN EYESIGHT" (MRS. DOHENY - 1947). false false 13738135 5929881 THE MISSION OF THE DOHENY EYE INSTITUTE (DEI), TO FURTHER THE CONSERVATION, IMPROVEMENT AND RESTORATION OF HUMAN EYESIGHT, IS GUIDED BY THE FOLLOWING OBJECTIVES: 1. TO INCREASE KNOWLEDGE OF THE HUMAN EYE, ITS CONDITIONS AND DISEASES, THROUGH RESEARCH; 2. TO TRANSMIT THIS KNOWLEDGE THROUGH EDUCATION, TRAINING, AND COMMUNITY SERVICE; AND 3. TO FACILITATE THE APPLICATION OF ITS RESEARCH TO IMPROVE PATIENT CARE AND FOSTER FURTHER RESEARCH. RESEARCH ACTIVITIES FOR THE PERIOD AND SELECTED FOR LONG-TERM FOCUS INCLUDE: RETINAL AND MACULAR DEGENERATION RESEARCH THROUGH THE STUDY OF RETINAL PIGMENT EPITHELIUM AND THE USE OF ADVANCED RETINAL IMAGING IN PATIENTS WITH AGE-RELATED MACULAR DEGENERATION (AMD) AND IMAGE ANALYSIS USING ARTIFICIAL INTELLEGENCE; MOLECULAR GENETICS OF INHERITED DISEASE OF THE RETINA AND GENE THERAPY FOR RETINAL DISORDERS; INVESTIGATIONS OF RETINAL VASCULAR STIFFNESS AS A POTENTIAL CAUSATIVE FACTOR IN DIABETIC RETINOPATHY AND AMD; RESEARCH FOCUSED ON DEFINING THE MOLECULAR DETAILS LINKING MITOCHONDRIAL DYSFUNCTION AND ALTERED SIGNALING BETWEEN RETINAL NEURONS. On December 18, 2013, the Doheny Eye Institute executed an agreement with the University of California at Los Angeles (UCLA) for a 99 year affiliation. The purpose of this affiliation is to carry out the Institute's mission -- to further the conservation, improvement, and restoration of human eyesight -- through research, education, and clinical care (clinical care is provided directly by UCLA). Both the Institute and UCLA-Stein Eye Institute are dedicated to providing the public with the highest quality of ophthalmic care and the most innovative and strategic research for the improvement of human eyesight. IN NOV. 2021 DOHENY EYE INSTITUTE (DEI) MOVED TO ITS NEW LOCATION - 150 ORANGE GROVE BLVD IN PASADENA, CA. NEW AREAS OF RESEARCH DEI IS STUDYING THE MECHANISMS RESPONSIBLE FOR DEVELOPMENT OF AGE-RELATED MACULAR DEGENERATION (AMD), THE NUMBER ONE CAUSE OF BLINDNESS AMONG INDIVIDUALS OVER 60 YEARS OLD IN THE USA. THE RISK OF DEVELOPING AMD IS SIGNIFICANTLY INCREASED WHEN SPECIFIC GENES ARE MUTATED. ONE NEW STUDY IS FOCUSED ON STUDYING THE RETINAL CELLS IN THE POPULATION OF PATIENTS HARBORING A SPECIFIC MUTATION IN A GENE INVOLVED IN THE IMMUNE SYSTEM. A SECOND STUDY IS FOCUSED ON A DIFFERENT GENE OF UNKNOWN FUNCTION BUT WITH HIGH IMPACT ON AMD. THE RESEARCHERS ARE STUDYING RETINAL CELLS GENERATED FROM AMD PATIENTS THAT HAVE THESE GENETIC DEFECTS. INFORMATION FROM THESE TWO STUDIES IS CRITICAL FOR DEVELOPMENT OF NEW THERAPIES FOR AMD THAT TARGET WHAT IS CAUSING THE DISEASE. IN OTHER STUDIES, DEI SCIENTISTS HAVE BEEN INVOLVED IN DEVELOPING NEW AND FASTER WAYS TO INTERPRET RETINAL IMAGES IN HUMAN PATIENTS USING ARTIFICIAL INTELLIGENCE (AI). IN TWO DIFFERENT STUDIES, AI-BASED APPROACHES FOR AUTOMATED INTERPRETATION OF IMAGES FROM PATIENTS WITH STARGARDT ATROPHY INCORPORATE INFORMATION FROM MULTIPLE IMAGING MODALITIES. ADDITIONALLY, BY FOLLOWING PATIENT IMAGES OVER TIME, AN AI-BASED AUTOMATED ALGORITHM IS BEING DEVELOPED TO PREDICT THE DEVELOPMENT AND PROGRESSION OF ATROPHY OVER TIME. DEI HAS DEVELOPED CUTTING EDGE IMAGING TECHNOLOGY, INCLUDING A NOVEL ADAPTIVE OPTICS NEAR-CONFOCAL OPHTHALMOSCOPE (AONCO) THAT ENABLES PRECISE EVALUATION OF THE DYNAMIC MOVEMENT OF ERYTHROCYTES WITHIN RETINAL CAPILLARIES, REFERRED TO AS "HIGHER-ORDER DYNAMICS". BY MONITORING ERYTHROCYTE VELOCITY WITHIN A CARDIAC CYCLE, THEY WILL VALIDATE THAT HIGHER ORDER HEMODYNAMICS IN RETINAL CAPILLARIES RESEMBLE THOSE CREATED FOR ASSESSING THE ARTERIAL STIFFNESS IN THE MACROVASCULAR SYSTEM. THIS WORK IS IMPORTANT BECAUSE WE WILL GAIN A BETTER UNDERSTANDING OF THE BLOOD FLOW OSCILLATIONS IN NORMAL HUMAN RETINAL CAPILLARIES AND DEVELOP NEW BIOMARKERS FOR DETECTING AGE- AND DISEASE-RELATED CHANGES IN THE RETINAL MICROCIRCULATION. DEI HAS ALSO DEVELOPED A PIONEERING ADAPTIVE OPTICS IMAGING INSTRUMENT THAT INTEGRATES SCANNING LASER OPHTHALMOSCOPY AND OPTICAL COHERENCE TOMOGRAPHY (AO-SLO-OCT). THIS INSTRUMENT CAN IMAGE THE RETINA WITH A 3-D SPATIAL RESOLUTION, ALLOWING FOR IN-VIVO ULTRASTRUCTURE ASSESSMENT OF INDIVIDUAL PHOTORECEPTORS IN BOTH EN FACE AND CROSS-SECTIONAL PLANES. THE IMPORTANCE IS THAT THIS ADAPTIVE OPTICS IMAGING OVERCOMES THE LIMITATIONS PRESENTED BY OPTICAL DEFECTS IN LIVING EYES, ALLOWING FOR HIGH RESOLUTION IMAGES OF NOT ONLY PHOTORECEPTORS, BUT ALSO THE CHORIOCAPILLARIS IN THE STUDY OF VARIOUS CHORIORETINAL DISEASES, INCLUDING AMD. ANOTHER IMAGING TECHNIQUE USED BY DEI SCIENTISTS IS THE USE OF CALCIUM IMAGING IN CONJUNCTION WITH CONFOCAL MICROSCOPY TO CHARACTERIZE THE EFFECTS OF OXIDATIVE STRESS ON THE RETINAL GANGLION CELLS. THESE EXPERIMENTS WILL IDENTIFY THE EARLY DEFICITS IN GANGLION CELL ELECTROPHYSIOLOGICAL FUNCTION RESULTING FROM MITOCHONDRIAL DYSFUNCTION. BY CAREFULLY ANALYZING THE EARLIEST SIGNS OF CHANGES TO PHOTORECEPTOR RESPONSE AND SYNAPTIC OUTPUT TO BIPOLAR CELLS, THIS DETECTION AND INTERPRETATION COULD LEAD TO DIAGNOSTIC CLUES THAT AID DETECTION OF PERSONS AT HIGHER RISK OF GLAUCOMA OR OPTIC NEUROPATHY. AN ADDITIONAL NEW AREA INVOLVES INVESTIGATIONS OF THE EARLY STAGES OF INFLAMMATION-MEDIATED DEGENERATION OF BLOOD VESSELS, FOCUSING ON THE ATROPHY OF INNER RETINAL VESSELS IN DIABETIC RETINOPATHY AND THE OUTER RETINAL BLOOD SUPPLY FROM THE CHORIOCAPILLARIS/CHOROID IN AMD. THIS INTEGRATION OF THE PRINCIPLES OF VASCULAR BIOLOGY, INFLAMMATION, AND MECHANOBIOLOGY, HAS LED TO A UNIQUE INTERDISCIPLINARY APPROACH THAT HAS THE POTENTIAL TO IDENTIFY CONTRIBUTIONS OF ALTERED VASCULAR STIFFNESS AS A PREVIOUSLY UNRECOGNIZED MECHANISM UNDERLYING THE PATHOGENESIS OF THESE PREVALENT OCULAR DISEASES. 13738135 true true false false false false false false false true true false false false true true true false false false false false false false false false false false false true false false false false false false false false false false false false false false false false false true 32 0 true 147 true true true false false false false false false false false false false false X 14 13 false false false false false false false true true false false true true true true true true true true false CA X X STEVE MACGREGOR 3233427100 150 ORANGE GROVE AVE PASADENA CA 91103 X MARISSA GOLDBERG CEO & SECRETARY 50.0 0.0 X X 656250 0 68485 SRINIVAS R SADDA MD Professor 37.5 0.0 X 326449 0 31148 Deborah Ann Ferrington Chief Scientific Officer 37.5 0.0 X 276250 0 8539 KENT BERKELEY TEPPER IT DIRECTOR 37.5 0.0 X 185974 0 30938 STEVEN DANIEL MACGREGOR DIRECTOR OF FINANCE 37.5 0.0 X 172232 0 43463 RAM KANNAN SCIENTIST 37.5 0.0 X 163721 0 27463 JAMES GIPSON VICE CHAIRMAN 3.0 0.0 X X 0 0 0 CHARLES T FOSCUE CHAIRMAN 1.5 0.0 X X 0 0 0 ROBERT L SMITH III DIRECTOR 0.25 0.0 X 0 0 0 JAY S WINTROB DIRECTOR 0.25 0.0 X 0 0 0 RONALD L OLSON DIRECTOR 0.25 0.0 X 0 0 0 STEPHEN A RALPH DIRECTOR 0.25 0.0 X 0 0 0 STEVEN E FELDON DIRECTOR 1.0 0.0 X 0 0 0 JOHN R CLEATOR DIRECTOR 0.25 0.0 X 0 0 0 KATHLEEN M DUNCAN DIRECTOR 0.25 0.0 X 0 0 0 GEOFFREY H GEE DIRECTOR 0.25 0.0 X 0 0 0 ERIC L SMALL DIRECTOR 0.25 0.0 X 0 0 0 ROBERT MALONEY DIRECTOR 0.25 0.0 X 0 0 0 MARK SAMUELS DIRECTOR 0.25 0.0 X 0 0 0 1780876 0 210036 6 false true false MAGINNIS KNECHTEL and McINTYRE LLP 300 W Colorado Blvd PASADENA CA 91105 AUDIT AND TAX 184500 Lindon Law Corporation 4010 Prado Del Trigo CALABASAS CA 91302 Legal 128830 2 3090948 2141140 5232088 CONTRACTS 900099 4863536 4863536 PASS THROUGH AWARDS 900099 489855 489855 OTHER REVENUE 900099 94490 61115 33375 5447881 1510442 1510442 0 11759 11759 0 0 0 47712291 34905285 12807006 12807006 0 0 0 0 0 0 0 0 0 REFUND FOR BUILDING PERMIT 900099 482000 482000 482000 25491176 5896506 33375 1522201 0 0 0 0 1780877 1124627 656250 0 8481986 6301532 1875911 304543 674666 451107 205492 18067 3191430 2133912 972056 85462 645297 431470 196547 17280 0 377796 208025 169771 121000 121000 0 0 0 240254 8529 210135 21590 80569 1080 73989 5500 1077501 159635 781531 136335 0 0 28340 28340 316233 278652 32354 5227 0 0 0 0 2529268 1264634 1239341 25293 333720 333720 MATERIALS AND SUPPLIES 1400201 1044094 356107 UTILITIES 710133 710133 TELEPHONE 270377 44740 224077 1560 CONSORTIUM 283434 283434 73936 2664 66588 4684 22617018 13738135 8253342 625541 X 10005184 33842236 0 0 666604 562282 1270279 1490655 0 0 0 0 0 0 0 0 362604 713370 109460248 5780017 101792134 103680231 111163274 82953786 0 0 0 0 0 0 4100585 4388596 229360664 227631156 2274487 2786884 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2399519 2110029 4674006 4896913 X 185233554 182086911 39453104 40647332 224686658 222734243 229360664 227631156 X 2874158 -5108026 281453 X false true X true true true X 6576201 4523302 7080057 3578935 5232088 26990583 0 0 6576201 4523302 7080057 3578935 5232088 26990583 2685839 24304744 1603923 1735130 1122641 1291559 1522201 7275454 79930 76534 33375 189839 0 0 0 0 482000 482000 34937876 34543553 0.69566 0.67323 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 32236904 5500 4558109 2657802 34142711 42699406 5000 -6980970 3486532 32236904 34555873 58765 10449330 2364562 42699406 36147175 230888 813027 2635217 34555873 35559613 20045 2859586 2292069 36147175 0.83000 0.17000 false false 25825643 25825643 74575679 2530253 72045426 8511353 3249764 5261589 547573 547573 103680231 0 REFUNDABLE ADVANCES 1386504 ANNUITY AGREEMENTS 723525 2110029 X 20665264 -5108026 282114 -4825912 25491176 25491176 22617679 661 661 22617018 22617018 INTENDED USES OF THE ORGANIZATION'S ENDOWMENT FUNDS SCH D PART V LINE 4 INTENDED USES OF THE ORGANIZATION'S ENDOWMENT FUNDS ARE TWOFOLD: 1. GENERATION OF FUNDS FOR RESEARCH PURPOSES; AND 2. GENERATION OF FUNDS FOR UNRESTRICTED PURPOSES. RECONCILIATION OF REVENUE SCH D PART XI, LINE 2D INCREASE IN VALUE OF SPLIT-INTEREST AGREEMENTS $ 282,114 SCH D PART XII, LINE 2D PENALTY ON FY22 CA TAXES ($ 661) FIN 48 FOOTNOTE SCH D PART X LINE 2 The Institute is a not-for-profit California corporation, granted tax-exempt status under Section 501(c)(3) of the Internal Revenue Code of 1986, as amended (the "Code"). The Institute is also exempt from California taxes, as a California Nonprofit Public Benefit Corporation. Accordingly, no provision has been made for income taxes. The Institute has analyzed its tax positions taken for filings with the Internal Revenue Service and State of California. It believes that its tax filing positions will be sustained upon examination and does not anticipate any adjustments that would result in a material adverse affect on its financial condition, results of operations or cash flows. United States federal and State of California returns have statutes of limitations that generally range from three to four years. No open tax years are currently under examination. X X false false false false false false false false false MARISSA GOLDBERG CEO & SECRETARY 525000 131250 30500 37985 724735 SRINIVAS R SADDA MD Professor 274192 52257 30500 648 357597 STEVEN DANIEL MACGREGOR DIRECTOR OF FINANCE 172232 17223 26240 215695 KENT BERKELEY TEPPER IT DIRECTOR 185974 18597 12341 216912 RAM KANNAN SCIENTIST 163721 16372 11091 191184 Deborah Ann Ferrington Chief Scientific Officer 276250 8539 284789 ANNUAL PERFORMANCE AND COMPENSATION REVIEW 990 PART VI LINE 15 DOHENY EYE INSTITUTE CONDUCTS AN ANNUAL PERFORMANCE AND COMPENSATION REVIEW. THIS WAS LAST CONDUCTED IN JUNE, 2023. THE INSTITUTE CONDUCTED COMPARISON FOR MANAGEMENT POSITIONS USING THE NON-PROFIT "CANDID 2022 22ND EDITION NON-PROFIT COMPENSATION REPORT". ANY PROPOSED SALARY FOR THE EXECUTIVES ARE REVIEWED AND APPROVED BY THE DOHENY EYE INSTITUTE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS PRIOR TO TAKING EFFECT. FORM 990 REVIEW 990 PART VI LINE 11A THE TAX PREPARER EMAILS A DRAFT COPY OF FORM 990 TO THE ORGANIZATION. THE DRAFT IS REVIEWED BY THE ORGANIZATION'S DIRECTOR OF FINANCE, CHIEF EXECUTIVE OFFICER, AND SENT TO THE BOARD OF DIRECTORS. COMMENTS AND QUESTIONS ARE EXCHANGED AND RESOLVED BOTH WITHIN THE ORGANIZATION AND BETWEEN THE ORGANIZATION AND THE TAX PREPARER. IF NECESSARY, A SECOND DRAFT IS CIRCULATED PRIOR TO ISSUING THE FINAL FORM 990 TO BE FILED. PUBLIC DISCLOSURE 990 PART VI LINE 19 The Organization's governing documents, conflict of interest policy, and recent federal income tax returns are made available for public inspection at the Organization's principal office during normal business hours. OTHER CHANGES IN NET ASSETS OR FUND BALANCES 990 PART XI LINE 9 CHANGE IN VALUE OF SPLIT-INTEREST AGREEMENTS: $ 282,114 PENALTY ON FY22 CALIFORNIA TAXES: ($ 661) --------------- TOTAL $ 281,453 CONFLICT OF INTEREST POLICY 990 PART VI LINE 12 Officers, directors, and key employees are required to complete and submit a conflict of interest questionnaire annually. The forms are tracked and reviewed by the executive committee. Should conflicts arise mid-year, according to the policy, the officer, director, or key employee would immediately be required to: (i) disclose the existence and circumstances of any transaction or relationship that could give rise to an actual or apparent conflict of interest with DEI, (ii) refrain from using personal influence to encourage DEI to take an action or decline to take an action involving such a transaction or relationship and (iii) recuse himself or herself from participation in any discussions or decisions regarding such transaction or relationship with directors, officers or key employees of DEI. This includes recusal during those portions of Board, Executive Committee or other Board committee meetings in which matters pertaining to such a transaction or relationship are being discussed, except to respond to requests for information about the transaction or relationship. Should any suspected or reported violations be found, the Chairman of the Board of Directors would promptly be notified and would then recommend appropriate action to the Executive Committee or the Board.